Veru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology, infectious disease and supportive care indications. Headquartered in Cambridge, Massachusetts, Veru leverages a diverse pipeline of small molecules and biologics to address unmet medical needs. The company’s research focuses on novel mechanisms of action designed to improve patient outcomes in areas including cancer, severe respiratory illness and hereditary angioedema.
Among Veru’s lead programs is sabizabulin, an oral, first-in-class microtubule inhibitor initially evaluated in severe COVID-19 patients at high risk of acute respiratory distress syndrome. The company has also advanced sabizabulin into oncology, exploring its potential efficacy in metastatic prostate cancer resistant to conventional therapies. Another key asset, enobosarm, is a selective androgen receptor modulator (SARM) being studied to prevent and treat muscle wasting in patients with hormone receptor-positive breast cancer and other malignancies. In addition, Veru markets Teslaris, an intravenous C1 esterase inhibitor approved for the prophylaxis of hereditary angioedema attacks in both pediatric and adult patients.
Founded in the early 2010s and formerly known as Celsus Therapeutics, Veru rebranded in 2015 to align with its expanding clinical focus. The company operates research and development facilities in North America and collaborates with academic medical centers and contract research organizations across the United States and Europe. Veru continues to pursue regulatory filings and strategic partnerships to broaden global access to its investigational therapies.
Under the leadership of founder, chairman and chief executive officer Mitchell Steiner, M.D., Veru is guided by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial strategy. The company’s board and scientific advisory panels include experts in oncology, virology and immunology, ensuring that Veru’s programs are informed by the latest advances in medical science. As Veru advances its portfolio through late-stage clinical trials, it remains committed to addressing critical patient needs in underserved therapeutic areas.
